1-20 of 39
Antoni Ribas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types

Razvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, Andrew Albright, Julie Kobie, Lingkang Huang, Qing Zhao, Anran Wang, Hua Ma, Z. Alexander Cao, Michael Morrissey, Antoni Ribas, Petros Grivas, David W. Cescon, Terrill K. McClanahan, Alexandra Snyder, Mark Ayers, Jared Lunceford, Andrey Loboda
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1680–1689.
https://doi.org/10.1158/1078-0432.CCR-21-3329
Published: 14 April 2022
View article titled, Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Open the PDF for Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types in another window
Includes: Supplementary data
Journal Articles

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Paolo A. Ascierto, Brigitte Dréno, James Larkin, Antoni Ribas, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Jessie Hsu, Surai Jones, Haocheng Li, Edward McKenna, Athina Voulgari, Grant A. McArthur
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5225–5235.
https://doi.org/10.1158/1078-0432.CCR-21-0809
Published: 01 October 2021
View article titled, 5-Year Outcomes with Cobimetinib plus Vemurafenib in <em>BRAF</em><sup>V600</sup> Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Open the PDF for 5-Year Outcomes with Cobimetinib plus Vemurafenib in <em>BRAF</em><sup>V600</sup> Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study in another window
Journal Articles

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

Jan C. Brase, Robert F.H. Walter, Alexander Savchenko, Daniel Gusenleitner, James Garrett, Tobias Schimming, Renata Varaljai, Deborah Castelletti, Ju Kim, Naveen Dakappagari, Ken Schultz, Caroline Robert, Georgina V. Long, Paul D. Nathan, Antoni Ribas, Keith T. Flaherty, Boguslawa Karaszewska, Jacob Schachter, Antje Sucker, Kurt W. Schmid, Lisa Zimmer, Elisabeth Livingstone, Eduard Gasal, Dirk Schadendorf, Alexander Roesch
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4500–4510.
https://doi.org/10.1158/1078-0432.CCR-20-3586
Published: 15 August 2021
View article titled, Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Open the PDF for Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib in another window
Includes: Supplementary data
Journal Articles

How Did We Get a COVID-19 Vaccine in Less Than 1 Year?

E. John Wherry, Elizabeth M. Jaffee, Nicholas Warren, Gypsyamber D'Souza, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2136–2138.
https://doi.org/10.1158/1078-0432.CCR-21-0079
Published: 15 April 2021
View article titled, How Did We Get a COVID-19 Vaccine in Less Than 1 Year?
Open the PDF for How Did We Get a COVID-19 Vaccine in Less Than 1 Year? in another window
Journal Articles

Autoantibody Landscape in Patients with Advanced Prostate Cancer

William S. Chen, Winston A. Haynes, Rebecca Waitz, Kathy Kamath, Agustin Vega-Crespo, Raunak Shrestha, Minlu Zhang, Adam Foye, Ignacio Baselga Carretero, Ivan Perez Garcilazo, Meng Zhang, Shuang G. Zhao, Martin Sjöström, David A. Quigley, Jonathan Chou, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Primo Lara, Kim N. Chi, Robert E. Reiter, Joshi J. Alumkal, Alan Ashworth, Rahul Aggarwal, Eric J. Small, Patrick S. Daugherty, Antoni Ribas, David Y. Oh, John C. Shon, Felix Y. Feng
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6204–6214.
https://doi.org/10.1158/1078-0432.CCR-20-1966
Published: 01 December 2020
View article titled, Autoantibody Landscape in Patients with Advanced Prostate Cancer
Open the PDF for Autoantibody Landscape in Patients with Advanced Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5086–5091.
https://doi.org/10.1158/1078-0432.CCR-20-0177
Published: 01 October 2020
View article titled, Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Open the PDF for Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B in another window
Includes: Supplementary data
Journal Articles

Abstract S03-01: Pan-HLA prediction of SARS-CoV-2 epitopes

Katie M. Campbell, Gabriela Steiner, Daniel K. Wells, Antoni Ribas, Anusha Kalbasi
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S03-01.
https://doi.org/10.1158/1557-3265.COVID-19-S03-01
Published: 15 September 2020
View article titled, Abstract S03-01: Pan-HLA prediction of SARS-CoV-2 epitopes
Journal Articles

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 46–53.
https://doi.org/10.1158/1078-0432.CCR-18-4180
Published: 03 January 2020
View article titled, Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <em>BRAF</em>-Mutant Melanoma
Open the PDF for Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer

Siwen Hu-Lieskovan, Aaron Lisberg, Jesse M. Zaretsky, Tristan R. Grogan, Hira Rizvi, Daniel K. Wells, James Carroll, Amy Cummings, John Madrigal, Benjamin Jones, Jacklin Gukasyan, I. Peter Shintaku, Dennis Slamon, Steven Dubinett, Jonathan W. Goldman, David Elashoff, Matthew D. Hellmann, Antoni Ribas, Edward B. Garon
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 5061–5068.
https://doi.org/10.1158/1078-0432.CCR-18-4275
Published: 15 August 2019
View article titled, Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer
Open the PDF for Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Response

Anu Sharma, Sumit K. Subudhi, Jorge Blando, Luis Vence, Jennifer Wargo, James P. Allison, Antoni Ribas, Padmanee Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3469–3470.
https://doi.org/10.1158/1078-0432.CCR-19-0402
Published: 03 June 2019
View article titled, Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers—Response
Open the PDF for Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers—Response in another window
Journal Articles

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3239–3246.
https://doi.org/10.1158/1078-0432.CCR-18-0720
Published: 01 June 2019
View article titled, Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma
Open the PDF for Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Theodore S. Nowicki, Beata Berent-Maoz, Gardenia Cheung-Lau, Rong Rong Huang, Xiaoyan Wang, Jennifer Tsoi, Paula Kaplan-Lefko, Paula Cabrera, Justin Tran, Jia Pang, Mignonette Macabali, Ivan Perez Garcilazo, Ignacio Baselga Carretero, Anusha Kalbasi, Alistair J. Cochran, Catherine S. Grasso, Siwen Hu-Lieskovan, Bartosz Chmielowski, Begoña Comin-Anduix, Arun Singh, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2096–2108.
https://doi.org/10.1158/1078-0432.CCR-18-3496
Published: 01 April 2019
View article titled, A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Open the PDF for A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab in another window
Includes: Supplementary data
Journal Articles

Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

Anu Sharma, Sumit K. Subudhi, Jorge Blando, Jorge Scutti, Luis Vence, Jennifer Wargo, James P. Allison, Antoni Ribas, Padmanee Sharma
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (4): 1233–1238.
https://doi.org/10.1158/1078-0432.CCR-18-0762
Published: 15 February 2019
View article titled, Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers
Open the PDF for Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3<sup>+</sup> Regulatory T Cells (Tregs) in Human Cancers in another window
Includes: Supplementary data
Journal Articles

IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System

Cristina Puig-Saus, Giulia Parisi, Angel Garcia-Diaz, Paige E. Krystofinski, Salemiz Sandoval, Ruixue Zhang, Ameya S. Champhekar, James McCabe, Gardenia C. Cheung-Lau, Nhat A. Truong, Agustin Vega-Crespo, Marie Desiles S. Komenan, Jia Pang, Mignonette H. Macabali, Justin D. Saco, Jeffrey L. Goodwin, Brad Bolon, Christopher S. Seet, Amelie Montel-Hagen, Gay M. Crooks, Roger P. Hollis, Beatriz Campo-Fernandez, Daniela Bischof, Kenneth Cornetta, Eric H. Gschweng, Celia Adelson, Alexander Nguyen, Lili Yang, Owen N. Witte, David Baltimore, Begonya Comin-Anduix, Donald B. Kohn, Xiaoyan Wang, Paula Cabrera, Paula J. Kaplan-Lefko, Beata Berent-Maoz, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (3): 1000–1011.
https://doi.org/10.1158/1078-0432.CCR-18-0963
Published: 01 February 2019
View article titled, IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System
Open the PDF for IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System in another window
Includes: Supplementary data
Journal Articles

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 6098.
https://doi.org/10.1158/1078-0432.CCR-18-3340
Published: 03 December 2018
View article titled, Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Journal Articles

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Curtis H. Kugel, III, Stephen M. Douglass, Marie R. Webster, Amanpreet Kaur, Qin Liu, Xiangfan Yin, Sarah A. Weiss, Farbod Darvishian, Rami N. Al-Rohil, Abibatou Ndoye, Reeti Behera, Gretchen M. Alicea, Brett L. Ecker, Mitchell Fane, Michael J. Allegrezza, Nikolaos Svoronos, Vinit Kumar, Daniel Y. Wang, Rajasekharan Somasundaram, Siwen Hu-Lieskovan, Alpaslan Ozgun, Meenhard Herlyn, Jose R. Conejo-Garcia, Dmitry Gabrilovich, Erica L. Stone, Theodore S. Nowicki, Jeffrey Sosman, Rajat Rai, Matteo S. Carlino, Georgina V. Long, Richard Marais, Antoni Ribas, Zeynep Eroglu, Michael A. Davies, Bastian Schilling, Dirk Schadendorf, Wei Xu, Ravi K. Amaravadi, Alexander M. Menzies, Jennifer L. McQuade, Douglas B. Johnson, Iman Osman, Ashani T. Weeraratna
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5347–5356.
https://doi.org/10.1158/1078-0432.CCR-18-1116
Published: 01 November 2018
View article titled, Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations
Open the PDF for Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations in another window
Includes: Supplementary data
Journal Articles

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (20): 4960–4967.
https://doi.org/10.1158/1078-0432.CCR-17-2386
Published: 15 October 2018
View article titled, Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Antigen Presentation Keeps Trending in Immunotherapy Resistance

Anusha Kalbasi, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (14): 3239–3241.
https://doi.org/10.1158/1078-0432.CCR-18-0698
Published: 15 July 2018
View article titled, Antigen Presentation Keeps Trending in Immunotherapy Resistance
Open the PDF for Antigen Presentation Keeps Trending in Immunotherapy Resistance in another window
Journal Articles

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1805–1815.
https://doi.org/10.1158/1078-0432.CCR-17-3436
Published: 12 April 2018
View article titled, Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Open the PDF for Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study in another window
Includes: Supplementary data
Journal Articles

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Matthew J. Wongchenko, Grant A. McArthur, Brigitte Dréno, James Larkin, Paolo A. Ascierto, Jeffrey Sosman, Luc Andries, Mark Kockx, Stephen D. Hurst, Ivor Caro, Isabelle Rooney, Priti S. Hegde, Luciana Molinero, Huibin Yue, Ilsung Chang, Lukas Amler, Yibing Yan, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5238–5245.
https://doi.org/10.1158/1078-0432.CCR-17-0172
Published: 31 August 2017
View article titled, Gene Expression Profiling in <em>BRAF</em>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib
Open the PDF for Gene Expression Profiling in <em>BRAF</em>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib in another window
Includes: Supplementary data